Ask AI

Unlocking the Full Potential of PROTAC ER Degraders in ER+/HER2- MBC: Novel Mechanisms, Testing Applications, and Data Insights to Address Unmet Needs

Enhance your ability to apply expert-guided treatment strategies for integrating PROTAC ER degraders into clinical practice based on current and emerging data supporting their use in patients with endocrine-resistant ER-positive/HER2-negative metastatic breast cancer through a certified text module, video modules, ClinicalThought commentaries, and accompanying downloadable slides.

Share

Program Content

Activities

PROTAC ER Degraders in MBC
Unlocking the Full Potential of PROTAC ER Degraders in ER+/HER2- MBC: Novel Mechanisms, Testing Applications, and Data Insights to Address Unmet Needs
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 17, 2025

Activities

PROTAC ER Degraders in MBC
Unlocking the Full Potential of PROTAC ER Degraders in ER+/HER2- MBC: Current Treatment Landscape and Unmet Needs for Patients 
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 10, 2026

Expires: August 09, 2026

Optimization of PROTAC ER Degraders
Current and Emerging Clinical Data: Expert Insights to Optimize PROTAC ER Degraders
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 11, 2026

Expires: August 10, 2026

Activities

PROTAC ER Degraders
Thoughts on Emerging PROTAC ER Degraders for Patients With Advanced HR+/HER2- Metastatic Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 01, 2025

PROTAC ER Degraders
PROTAC ER Degraders in ER-Positive/HER2-Negative MBC Progressing After Endocrine Therapy: Latest Updates From SABCS 2025
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 20, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Pfizer, Inc. and Arvinas.

Arvinas

Pfizer, Inc.